Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
02:00pm, Tuesday, 31'st Aug 2021
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals
Why Shares of Ascendis Soared This Week
09:46pm, Thursday, 26'th Aug 2021
The pharmaceutical company saw its shares jump more than $26.
Here's Why Ascendis Pharma Shares Are Surging Higher Today
02:13pm, Thursday, 26'th Aug 2021
Approval of the company's weekly growth hormone is making investors smile today.
See Why Ascendis Pharma Stock Is Shining On Thursday
11:34am, Thursday, 26'th Aug 2021
The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in k
ASND Stock: Over 20% Increase Pre-Market Explanation
07:46am, Thursday, 26'th Aug 2021
The stock price of Ascendis Pharma A/S (Nasdaq: ASND) increased by over 20% pre-market. This is why it happened.
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2021 Results - Earnings Call Transcript
01:37am, Thursday, 26'th Aug 2021
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2021 Results - Earnings Call Transcript
These 2 Stocks Soared Double Digits After Hours
06:20pm, Wednesday, 25'th Aug 2021
Find out where the big winners were late Wednesday.
Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results
04:12pm, Wednesday, 25'th Aug 2021
– Announced U.S. Food and Drug Administration Approval of SKYTROFA ® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency –
- SKYTROFA, the first FDA approved treatment utilizing TransCon™ technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies –
Is a Surprise Coming for Ascendis Pharma (ASND) This Earnings Season?
09:56am, Monday, 23'rd Aug 2021
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25
04:17pm, Tuesday, 17'th Aug 2021
COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidate
Ascendis Pharma A/S Announces Upcoming Investor Presentations in August
07:05am, Friday, 06'th Aug 2021
COPENHAGEN, Denmark, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candi
Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension
11:17am, Monday, 14'th Jun 2021
Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.
Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months
07:23am, Monday, 14'th Jun 2021
The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the treatment of pediatric growth hormone deficien
Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021 Prescription Drug User Fee Act (PDUFA) goal date extended by three mont
